Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Third Rock Ventures
Biotech
After 'complete standstill,' biotech market reaches new normal
The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several areas, such as cardiorenal and neuropsych.
Gabrielle Masson
Aug 20, 2025 11:04am
Third Rock-backed Merida unveils with $121M for autoimmune plans
Apr 8, 2025 11:03am
Marea, Ashibio, Arvinas & more—Chutes & Ladders
Jun 21, 2024 8:30am
Marea ropes in $190M for clinical-stage cardiometabolic program
Jun 18, 2024 7:00am
Rapport upsizes IPO, tacking on $32M
Jun 7, 2024 11:00am
Third Rock, J&J neuroscience spinout Rapport outlines IPO plans
May 20, 2024 5:13am
